A Phase 1, open-label, randomized dose proportionality study of Technosphere[R] insulin inhalation powder
(TI) doses up to 80 U administered with the Gen2 inhaler in healthy subjects.
Boss, "A phase 1, open-label, randomized dose proportionality study of technosphere[R] insulin inhalation powder
(TI) doses up to 80 u administered with the gen2 inhaler in healthy subjects," Diabetes, vol.
In an open-label, randomized, crossover study, Garg et al (48) compared preprandial human insulin inhalation powder plus insulin glargine to preprandial subcutaneous (SC) insulin (lispro or regular) plus insulin glargine.
Clinical trials of a human insulin inhalation powder in subjects with type 1 diabetes reported similar rates of total hypoglycemic episodes with inhaled and SC insulin in both conventional and intensive insulin therapy.